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We have examined the interaction of thrombin with 
fibrinogen Aa chain residues 7-16. Using genetically 
engineered constructions, we have synthesized in 
Escherichia coli a fibrinogen Aa l-50 fusion protein 
and seven mutant proteins with single amino acid sub- 
stitutions. These are: Asp’ + Ala, Phe’ + Tyr, Glu” + 
Ala, Gly’* + Val, Gly13 + Val, Gly14 -+ Val, and Arg” 
+ Leu. Competitive immunoassay of cell lysates 
showed that all the mutations but one, Arg” + Leu, 
altered the structure of the protein such that cross- 
reactivity with the Aa-specific monoclonal antibody, 
Y18, was significantly reduced. The fusion proteins 
were purified and analyzed as thrombin inhibitors and 
substrates. All the fusion proteins are competitive in- 
hibitors of the amidolytic hydrolysis of Spectrozyme 
TH, a thrombin-specific chromogenic substrate, with 
inhibition constants corresponding to that for fibrino- 
gen. We conclude that these 7 amino acid substitutions 
do not alter thrombin binding to the fusion proteins. 
The fusion proteins were tested as substrates by mon- 
itoring thrombin-dependent peptide release. The nat- 
ural sequence and three mutants, Asp7 + Ala, Glu” 4 
Ala, and Gly14 -) Val, are good substrates. The other 
mutants are either poor substrates or are not cleaved 
by thrombin within Aa l-50. These results indicate 
that residues between Asp7 and Argl’ are critical to 
efficient peptide hydrolysis, whereas residues outside 
this region are critical to thrombin binding. 
The conversion of soluble fibrinogen to an insoluble fibrin 
clot is catalyzed by the serine protease thrombin. Thrombin 
cleaves four peptide bonds in fibrinogen, the Arg”-Gly17 bonds 
in each of the two Aa chains, releasing FpA,’ and the Arg14- 
Gly15 bonds in each of the two B/Z? chains, releasing FpB. 
Previous investigations demonstrated that the CNBr frag- 
ment Aoc l-51 contained all the residues required for thrombin 
recognition and cleavage of the A& chain (1, 2). Using an 
active site mapping approach, Scheraga and his colleagues 
have shown that, in particular, residues between Asp’ and 
Val*’ are important (3-5). The specificity constant, !z~,~/K,, 
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for the peptide Aol Aspy-ValZO was only lo-fold lower than 
that for Aa 1-51 (5). Recently, NMR techniques have been 
used to study the structures of synthetic Aol peptides free in 
solution and bound to bovine thrombin (6, 7). Results from 
these experiments indicated that thrombin recognizes a pep- 
tide structure which includes a tight turn between Asp7 and 
Arg” and that several residues within this region are directly 
involved in the peptide-thrombin complex (7). Based on these 
and additional NMR studies, model structures were proposed 
for the decapeptide Asp7-Arg” bound to thrombin (8). 
We have initiated experiments to examine the significance 
of these and other residues in ALY l-50 to the thrombin- 
fibrinogen interaction. We approached this problem using 
genetic engineering to synthesize a model thrombin substrate 
in Escherichia coli (9). This model substrate is a tripartite 
protein consisting of Aa residues l-50 linked by a 59-residue 
segment of collagen to E. coli p-galactosidase. Previously, we 
reported that thrombin cleavage of the recombinant protein 
in crude cell lysates approximated thrombin cleavage of fi- 
brinogen (9). The data presented here demonstrates that the 
purified recombinant protein is remarkably similar to native 
fibrinogen in its interaction with thrombin. Using directed 
mutagenesis, we have synthesized seven analogous proteins 
with single amino acid substitutions between residues 7 and 
16. Analysis of the mutated proteins indicates that this region 
of Aol is critical to efficient peptide hydrolysis, but is less 
important to thrombin binding. A preliminary report of these 
results has been presented (10). 
EXPERIMENTAL PROCEDURES 
Materials-Restriction enzymes, polynucleotide kinase, and T4 
DNA ligase were purchased from New England Biolabs. Isopropyl-P- 
D-thiogalactopyranoside was obtained from United States Biochem- 
ical Corp. Phenylmethanesulfonyl fluoride, o-nitrophenyl-@-D-galac- 
topyranoside, p-aminophenyl-1-thio$-D-galactopyranoside, l-ethyl- 
3-(3-dimethylaminopropyl)carbodiimide, 6-aminohexanoic acid- 
Sepharose 4B, and chemicals for buffers and media were purchased 
from Sigma. Spectrozyme@TH (H-D-hexahydrotyrosyl-L-alanyl+ar- 
ginine-p-nitroanilide) was purchased from American Diagnostica, 
Inc., human fibrinogen, Grade L, from KabiVitrum, the Vydac Cl8 
cartridge column from Alltech Applied Science Labs, and human 
fibrinopeptide A (FpA) from Bachem Bioscience, Inc. Human (Y- 
thrombin was the generous gift of Dr. Roger Lundblad (Department 
of Pathology, University of North Carolina). 
Mutant Plasmid Construction-The DNA segment encoding amino 
acids l-50 of the Aa chain of human fibrinogen was assembled from 
seven oligonucleotides and cloned as previously described (9). TWO of 
the seven oligonucleotides, presented in Fig. lA, each contained 
equimolar mixtures of 2 bases at three positions. DNA from cloned 
isolates, each containing a single coding sequence, was prepared and 
sequenced as described (9). E. coli strain JMlOl (supE, thi, A(lac- 
pro), [F’, traD36, proAB, lacqZAM15) was used for all cloning and 
expression experiments. Cells harboring plasmid were grown in me- 
dium containing ampicillin (100 pg/ml). 
Tribrid Protein Purification-Cells harboring the plasmid expres- 
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sion vector were grown in 10 liters of 2 x YT fermentation medium 
(11) in a MagnaFerm Bench Top Fermentor Model MA-100 (New 
Brunswick Scientific Co.). Cultures were started the previous day 
from a single colony and grown in 5 ml of M9 (11) throughout the 
day. A series of IO-fold dilutions from 1:lO to l:lO,OOO were prepared 
from the 5-ml culture and grown overnight at 37 “C in M9. The 
overnight culture with OD,,, - 0.5 was used to inoculate 500 ml of 2 
X YT. This culture was grown for 2 h and used to inoculate the lo- 
liter fermentor vessel. Cells were grown to ODego = 8 (usually 2 h) at 
which time isopropyl-/3-D-thiogalactopyranoside was added to 1 mM 
and lactose to 5 mM. During fermentation the pH was maintained at 
7, and the @-galactosidase activity was monitored by a calorimetric 
assay with o-nitrophenyl-P-D-galactopyranoside as substrate (11). 
When the /+galactosidase activity plateaued, the cells were harvested 
by centrifugation and stored at -20 “C. 
The tribrid was purified by a combination of previously published 
procedures (12, 13). Frozen cell paste was resuspended in 0.05 M Tris- 
HCl, pH 8.0, 15% sucrose, 0.05 M EDTA (1 g of cell paste/5 ml of 
buffer) to which 1 mg/ml lysozyme had been added. The cells were 
incubated on ice 30 min and then frozen at -70 “C. After a quick 
thaw, the cells were sonicated briefly, phenylmethanesulfonyl fluoride 
added to 1 mM, and the suspension centrifuged at 27,000 X g for 30 
min at 4 “C. Nucleic acids were precipitated by dropwise addition of 
30% streptomycin sulfate (12). The supernatant was adjusted to 1.6 
M NaCl and applied to a p-aminophenyl-l-thio-fl-n-galactopyrano- 
side-Sepharose column (13). A 3 x 7-cm column was routinely used 
for 24 g of frozen cell paste. The tribrid was eluted with 0.1 M sodium 
borate, pH 10.5, and fractions were promptly precipitated with 40% 
ammonium sulfate (12). The fractions were assayed for P-galactosid- 
ase activity and the active fractions pooled and centrifuged at 12,000 
x g for 20 min at 4 “C. The tribrid precipitate was dissolved in and 
dialyzed overnight against 0.05 M Tris-HCl, pH 8.3, 0.15 M NaCl, 
0.02% sodium azide, 0.1% polyethylene glycol 8000 (TSAP) at 4 “C. 
The purity of the tribrid was monitored as units of p-galactosidasel 
mg of protein, measured by the Bradford Assay (Bio-Rad). SDS- 
PAGE (14) and protein blot analysis were as described previously (9). 
Competitive Enzyme-linked Immunosorbent Assay-A competitive 
cross-reactivity assay similar to that described by Koppert et al. (15) 
was used to quantitate the interaction between the recombinant 
proteins and the monoclonal antibody Y18. A working dilution of 
peroxidase-conjugated Y18 (Y18/HRP, kindly provided by W. Nieu- 
wenhuizen) was determined by serial dilution, selecting a concentra- 
tion within the linear range. E. coli cells were grown and lysates 
prepared (9) and diluted with 0.01 M Tris-HCl, pH 8.0, 0.15 M NaCl, 
0.05% Tween-20. Tribrid concentration was quantitated as P-galac- 
tosidase activity based on the ratio of FpA/@-galactosidase activity 
for the An tribrid (9). YlS/HRP was incubated with cell lysates 
overnight at 4 “C and cross-reactivity was quantitated on fibrinogen- 
coated microtiter plates, using hydrogen peroxide and 2,2’-azino-di- 
(3.ethylbenzthiazopine sulfonate) (Kirkegaard and Perry Laborato- 
ries) as substrates. Results were determined on a Molecular Devices 
kinetic microplate reader with a 405-490-nm filter. Fibrinogen was 
assayed in the presence of an E. coli lysate not expressing the tribrid. 
Percent inhibition was determined as [l-(absorbance with competi- 
tor/absorbance without competitor)] X 100%. 
protein and densitometry of Coomassie-stained gels using an LKB 
Ultroscan XL laser densitometer. Results from multinle scans were 
Inhibition of Synthetic Substrate Hydrolysis-Various concentra- 
tions of Spectrozyme TH, from 1 to 10 x K,,,, were incubated with 
human a-thrombin (0.02 unit/ml) either alone, with fibrinogen, or 
with purified tribrid. The concentration of enzymatically hydrolyza- 
ble Spectrozyme TH was determined after incubating for 2 h with 
200 units/ml thrombin, using an extinction coefficient E,,s = 9920 
M-i cm-’ for p-nitroaniline (17). Aliquots of a-thrombin were stored 
at -70 “C, and a fresh sample was thawed and diluted in TSAP 
immediately before use. Fibrinogen was dialyzed against TSAP at 
4 “C and the concentration determined with the extinction coefficient 
E?% = 15 (18). Tribrid concentrations were determined from total 
temperature with constant mixing. Initial velocity measurements 
were determined at or below 20% conversion of substrate to product. 
Michaelis-Menten parameters were obtained by using the nonlinear 
regression analysis program Enzfitter (Biosoft, Inc.). 
HPLC Analysis of Tribrid Hydrolysis-Fibrinopeptides released by 
thrombin digestion were analyzed by an LKB HPLC system which 
includes a 2157 Autosampler, a 2152 HPLC Controller, a 2150 HPLC 
pump, a 2138 Uvicord S detector with a 206~nm filter, and a 2211 
Superrac Fraction Collector. An isocratic solvent system (0.1% triflu- 
oroacetic acid in 20% acetonitrile) (19) was used with a flow rate of 
0.5 ml/min on a Vydac Cl8 reversed-phase column (250 X 4.6 mm, 
particle size 10 Gm). 
Samples were prepared essentially as described (20). Recombinant 
tribrid was incubated with a-thrombin which was diluted in TSAP 
buffer (0.02-20 units/ml) immediately before use. The reaction pro- 
ceeded at ambient temperature and was terminated by heating for 
two min at 90 “C. Precipitate was removed by centrifugation at 4 “C 
for ten min at 13,600 X g. The supernatant was filtered with a 0.2- 
pm low protein binding filter (Gelman Sciences) before HPLC analy- 
sis. Peptide concentrations were quantitated by comparing the peak 
area to a calibration curve with a standard human fibrinopeptide A 
solution. 
Fractions containing tribrid peptides were collected and analyzed 
for amino acid content. Peptide solutions were evaporated to dryness 
and hydrolyzed by gas-phase hydrolysis at 165 “C for 1 h. Samples 
were analyzed with Applied Biosystems Inc. equipment including a 
Model 470 Derivatizer, a Model 120 phenylthiohydantoin Analyzer, 
and a Model 920 Data Analysis Module. 
RESULTS 
Construction of M?tunt Genes-Plasmid expression vectors 
encoding substitutions in fibrinogen ALY 7-16 were con- 
structed by oligonucleotide assembly as described previously 
(9) using the oligonucleotides listed in Fig. 1A. Cloned isolates 
were characterized by DNA sequence analysis. We sequenced 
70 clones, identifying six mutants with single, seven mutants 
with double, and three mutants with triple amino acid substi- 
tutions. We have analyzed the six recombinant proteins with 
single substitutions, Asp7 + Ala (D7A), Phe* + Tyr (3’8Y), 
u’l + Ala (EllA), Gly’* + Val (G12V), Gly13 + Val 
El3V) and Arg” + Leu (R16L), along with a mutant, Gly14 
+ Val \G14V), identified previously (9). The mutants are 
listed in Fig. 123. 
Cross-reactivity Assays-Protein blot analysis of lysates 
harboring the tribrid plasmids using a monoclonal antibody 
to &galactosidase (data not shown) demonstrated that all the 
A. Mutagenic oligonucleotides used in this Aa assembly: 
T T T 
1. 5’ GCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAA 
AEGGGVRGPRVVERHQ 
v v L 
G T G 
2. 3’ CGTCTATCACCACTTCCACTGAAAGATCGATCGACTTCCTCCTCCGCACGCACCG 
ADSGEGDFLAEGGGVRG 
A Y A 
B. Substitutions used in this study: D7A--position 7 substitutes Ala for Asp 
FEY--position 8 substitutes Tyr for Phe 
El IA--position 1 I substitutes Ala for Glu 
GIZV--position 12 substitutes Val for Gly 
GI3V--position 13 substitutes Val for Glr 
Gl4V--&tion 14 substitutes Val for Gly 
Rl6L--position 16 substitutes Leu for Arg 
averaged to give the percent purity. Where possible, the concentration 
of tribrid was also determined by HPLC (see below), quantitating 
FpA release after incubating the tribrid with 200 units/ml a-thrombin 
at 37 “C for 2 or more h. Since no FpA-like peptide was released from 
the F8Y tribrid, we relied solely on the densitometry scan for this 
mutant. Thus, the particularly low value for F8Y (R = 1.5 FM) may 
be misleading. 
Inhibition assays were performed in microtiter plates with a Mo- 
lecular Devices kinetic reader as described (16). Reactions were 
initiated by the addition of thrombin and incubated at ambient 
FIG. 1. Nucleotide and peptide sequences of tribrid clones. 
A, oligonucleotides used to assemble the vector for expressing natural 
and mutated tribrids. Below the DNA sequences are the amino acids 
(single letters) encoded by these oligonucleotides. The mixed bases 
were equimolar for the two bases noted. Oligonucleotides 1 and 2 here 
correspond to numbers 3 and 2, respectively, in Fig. 1 of Lord and 
Fowlkes (9). B, single amino acid substitutions in the Acu chain 
segment of human fibrinogen. The plasmids encoding these mutant 
proteins are similarly denoted; for example the plasmid pD7A encodes 
the tribrid where position 7 is Ala. 
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mutated tribrid proteins migrated on SDS-PAGE with the 
predicted mobility, 127 kDa, and all the mutants were syn- 
thesized at the same level as the tribrid carrying the natural 
Acu sequence. Western blot analysis using a monoclonal an- 
tibody, Y18, whose epitope maps within Aa 1-51 (15) dem- 
onstrated that only some of the mutated proteins cross-react 
with this antibody. To quantitate this cross-reactivity, we 
analyzed the recombinant proteins in a competitive enzyme- 
linked immunosorbent assay where the test antigen was prein- 
cubated in solution with Y18/HRP and then assayed on 
microtiter plates coated with fibrinogen. The results are pre- 
sented in Fig. 2. By comparing the quantity of antigen which 
gives 50% inhibition, it was found that both the natural 
recombinant protein and the R16L mutant reacted strongly 
with Y18, within an order of magnitude of fibrinogen. Com- 
pared to the Aa tribrid, the D7A substitution reduced cross- 
reactivity more than lo-fold, whereas the F8Y substitution 
reduced cross-reactivity more than loo-fold. The other mu- 
tants, EllA, Gl2V, Gl3V, and Gl4V, did not cross-react with 
Y18. 
Tribrid Protein Purification-The tribrid proteins were pu- 
rified by affinity chromatography based on their P-galactosid- 
ase activity. As shown by SDS-PAGE, Fig. 3, this single 
chromatography step resulted in a virtually pure preparation 
of the tribrid. A major contaminant of -110 kDa was seen in 
most preparations. This protein cross-reacted with the mono- 
clonal antibody to P-galactosidase (9) and therefore is prob- 
ably the truncated protein (predicted mass = 113 kDa) (22) 
encoded by the lacZAM15 gene in JMlOl. Although this 
truncated protein is not catalytically active, it retains the 
substrate binding site (22) and, therefore, bound to the sub- 
strate analog matrix. Control experiments indicated that this 
protein did not interfere with the tribrid assays. Other minor 
contaminants, -50 kDa, were reproducibly present; these 
proteins did not cross-react with the P-galactosidase mono- 
clonal antibody. The concentration of tribrid protein, quan- 
titated by scanning laser densitometry of the Coomassie- 
stained gels, varied from 30 to 65% of the total purified 
protein. As shown in Table I, purification resulted in about a 
250-fold increase in specific activity, indicating that the tri- 
brid represented O.l-0.3% of total cellular protein. 
Thrombin Inhibition-The tribrid proteins were analyzed 
as inhibitors of thrombin-catalyzed cleavage of the chromo- 
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FIG. 2. Competitive enzyme-linked immunosorbent assays 
with mAb Y18. Competitor and antibody were incubated for 18 h 
at 4 “C, and cross-reactivity was quantitated on fibrinogen-coated 
microtiter plates. Tribrid concentrations were determined from p- 
galactosidase activity as described under “Experimental Procedures.” 
V, fibrinogen; 0, An tribrid: Cl, R16L; A, D’iA, A, F8Y. 
A B C 
Mr (kD) 
- -200 
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FIG. 3. SDS-PAGE analysis of tribrid purification. An 8% 
polyacrylamide gel stained with Coomassie Blue. A, approximately 
15 fig of protein sampled before affinity chromatography. B, 2 pg of 
purified tribrid. The band marked with an arrow is the lacZAM15 
protein synthesized by the host cell. C, molecular mass standards: 
(200 kDa) myosin, (97 kDa) phosphorylase 6, (68 kDa) bovine serum 
albumin, (43 kDa) ovalbumin, (26 kDa) a-chymotrypsinogen, (18 
kDa) a-lactoglobulin, (14 kDa) lysozyme. 
TABLE I 
Purification of tribrid protein 
Assays were performed as described under “Experimental Proce- 
dures.” This preparation was from 24 g of frozen cell pellet. 





Protein f&Gal Specific Purifi- activity activity cation Recovery 
x lo+ 
w units/ml units/n+! -fold % 
3.2 x 10” 27 0.8 x 10” 100 
1.8 x 10” 22 1.2 x lo3 1.5 81 
3.2 6.5 2.0 x 10” 250 24 
TABLE II 
Summary of kinetic analysis 
Substrate hydrolysis* 
Substrate Spectrozyme inhibition KP 50% cleavage Thrombin Cleavage 
time concentration site 
I.rM min units/ml 
Fibrinogen 5.7 + 3.5 (7) 25 f 2 0.02 Arg” 
Aa tribrid 3.5 k 3.0 (6) 44 + 2 0.02 Arg” 
D7A 4.5 f 2.1 (9) 61 f 17 0.02 Arg” 
F8Y 1.5 f 0.7 (3) -c - - 
E1lA 5.8 + 2.2 (3) 33 f 23 0.02 Arg” 
G12V 8.9 + 6.3 (4) 109 f 24 2.0 Arg’” 
G13V 6.9 + 6.3 (2) 51 f6 2.0 Arg” 
G14V 5.4 f 3.7 (4) 28 + 2 0.02 Arg” 
R16L 5.0 + 0.5 (3) 69 f 25 2.0 Arglg 
’ All inhibition assays were with 0.02 unit/ml a-thrombin. Results 
are expressed as mean + S.D. The numbers in parentheses indicate 
the number of experiments. 
b Substrate concentrations were all 5 mM. Results are expressed as 
mean f S.D. (n = 3). 
’ No peptide was isolated from F8Y. 
genie substrate Spectrozyme TH. As described under “Exper- 
imental Procedures,” initial velocity measurements were de- 
termined at or below 20% substrate hydrolysis. The kinetic 
data are summarized in Table II and a representative Line- 
weaver-Burk plot is shown in Fig. 4. The K, determined for 
Spectrozyme TH was 5.8 pM, a value slightly larger than that 
reported by the supplier, 3.2 pM. The mutant tribrids all 
inhibited Spectrozyme TH hydrolysis equally and to the same 
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FIG. 4. Lineweaver-Burk plot of representative inhibition 
data. As described under “Experimental Procedures,” Spectrozyme 
TH was incubated with 0.02 unit/ml thrombin either alone, with 
fibrinogen, or with purified tribrid. The plots are directly from the 
Enzfitter analysis. Similar analysis was used to determine the Ki 
values listed in Table II. 0, no additions; 0, +lO pM control tribrid; 
A, +6 pM G12V; 0, +9 pM fibrinogen. 
100 L’ 
Time (min) 
FIG. 5. Progress curves of thrombin catalysis. Rates of re- 
lease of FpA and FpA-like peptides were determined by HPLC as 
described under “Experimental Procedures.” All substrates were 5 
PM. The concentration of thrombin was 0.02 unit/ml except for 
substrate G12V where thrombin was 2 unit/ml. 0, fibrinogen; 0, 
Gl4V; A, Aa tribrid; n , Gl2V. 
extent as the natural tribrid. Furthermore, within experimen- 
tal error, the tribrids all inhibited as well as human fibrinogen. 
To insure that this inhibition was due to the presence of Aa 
l-50 in the tribrid, we tested an analogous protein in which 
these 50 residues were replaced by an unrelated 121-residue 
segment. This protein, purified as described for the Acu tri- 
brids, did not inhibit Spectrozyme TH hydrolysis (Fig. 4). 
Thrombin Substrates-Purified fusion proteins were tested 
as thrombin substrates using HPLC to follow peptide release. 
Typical progress curves are presented in Fig. 5 and the data 
are summarized in Table II. Because thrombin cleaves Aoc l- 
51 after both Arg” and Arglg, although the latter at a signifi- 
cantly slower rate (3), we performed amino acid analysis on 
the released peptide to determine where cleavage occurred. 
The data, summarized in Table III, show that all the tribrid 
substrates were cleaved after Arg” except R16L, which was 
cleaved after Arglg. 
Several of the tribrid proteins were good thrombin sub- 
strates as compared with fibrinogen. Three mutant tribrids, 
TABLE III 
Amino acid composition of thrombin-rekased peptides 
Aa-tribrid D7A EllA G12V G13V G14V R16L 
Ala 2.0 (2Y 3.0 3.0 2.0 2.0 2.0 2.0 
Anz 1.0 (1) 0.8 1.1 1.0 0.9 1.3 1.1 
ASP 1.8 (2) 1.0 2.0 1.6 1.9 2.0 2.0 
Glu 2.1 (2) 2.5 1.3 2.2 2.0 2.1 2.2 
GUY 4.7 (5) 5.6 4.9 4.6 4.0 3.9 6.2 
Leu 1.2 (1) 1.0 1.3 1.2 1.1 1.4 2.1 
Phe 1.0 (1) 0.9 0.9 1.0 1.0 1.0 0.9 
Pro (0) 1.1 
Ser 1.0 (1) 
0.9 (1) i::: 
1.1 1.0 1.0 1.0 1.1 
Val 0.9 1.8 1.8 1.4 0.9 
a Theoretical values for FpA are in parentheses (25). 
D7A, EllA, and Gl4V, were cleaved as readily as the natural 
tribrid. Interestingly, the mutant Gl4V was apparently 
cleaved more rapidly than the natural sequence. Three other 
mutants, Gl2V, Gl3V, and Rl6L, were cleaved much more 
slowly, requiring loo-fold more thrombin for cleavage to occur 
within the same time frame as the good substrates. Using a 
gradient elution for HPLC, we isolated another peptide from 
the digestion of G12V with 2 units/ml thrombin. The amino 
acid composition of this peptide was consistent with a peptide 
starting at ValzO and ending at Arg@‘, the 17th residue of the 
collagen linker. This result (data not shown) indicates that at 
this higher enzyme concentration, thrombin also cleaved all 
the tribrids after Arglg in the (Y sequence and after an arginine 
in collagen. 
The mutant F8Y tribrid has been extensively analyzed with 
no definitive result. At 20 units/ml of thrombin no FpA-like 
peptide was found by isocratic HPLC. However, Western blot 
analysis with mAb Y18 of thrombin-treated F8Y demon- 
strated that the cross-reacting band at 127 kDa was lost after 
incubation with 20 units/ml of thrombin. Accordingly, it is 
likely that thrombin cleaved this tribrid in the collagen linker, 
removing the Y18 reactive domain. Although no definitive 
data were obtained to indicate such a specific cleavage, it 
appears that thrombin did not cleave F8Y after either Arg” 
or Arglg. 
DISCUSSION 
The experiments described here were designed to examine 
the significance of Aa residues Asp7-Arg” to thrombin-cata- 
lyzed hydrolysis of fibrinogen. We constructed a recombinant 
model substrate and modified substrates with altered residues 
in this region. Analysis of crude lysates demonstrated that all 
the recombinant proteins were synthesized similarly; that is, 
mutation per se did not alter the level of tribrid synthesis. 
Because the recombinants included active fi-galactosidase, 
these proteins were readily purified by affinity chromatogra- 
phy on a substrate analog matrix. 
The reduced cross-reactivity with mAb Y18 readily dem- 
onstrated that most of our mutant tribrids have altered struc- 
tures. Only the tribrid with the Rl6L substitution cross- 
reacted strongly, indicating that Arg” is not a critical part of 
the epitope. This is in contrast to the loss of reactivity between 
Y18 and dysfibrinogen Metz, where Arg” is replaced by Cys 
(15). Together these data suggest that the Cys substitution 
causes a change in the conformation of this important amino- 
terminal domain. This change may simply make the mAb Y 18 
epitope inaccessible. 
The results from the Spectrozyme TH experiments dem- 
onstrate that all the Aa-tribrids are good competitive inhibi- 
tors of amidolytic activity. The values for K; are the same and 
importantly are the same as that for fibrinogen. Our data lack 
precision because of difficulties in determining the tribrid 
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concentration, due mostly to contamination by the lacZAM15 
gene product. However, the results indicate that among all 
these inhibitors there is at most a 5-fold difference in affinity 
for thrombin. 
Although all the tribrids are good inhibitors, several mutant 
tribrids are not good substrates. The reduced reactivity found 
with RI6L and G12V is not surprising in light of previously 
reported data. The specificity of thrombin per se leads one to 
expect that the Leu’6-Gly’7 bond would not be cleaved at all 
and that cleavage at the Arg”-Val*’ bond would be slow (3). 
The G12V mutant in dysfibrinogen Rouen is a poor thrombin 
substrate (23), so the reduced reactivity of this mutant is 
expected. The reduced reactivity of G13V is consistent with 
the thrombin-bound peptide model structure (8), where G13 
is the third residue of a P-turn, a position where glycine is 
strongly preferred (24). This residue is further constrained by 
backbone hydrogen bonds via its a-amino to the ol-carbonyl 
of Leug and via its cY-carbonyl to the a-amino of Arg”. 
Consequently, alteration of this residue is likely to disrupt 
the structure of the bound peptide and reduce the rate of 
catalysis. The observation that the F8Y mutant appears not 
to be cleaved in Aol is consistent with the preservation of this 
residue throughout evolution (25) and with the kinetic data 
for synthetic peptides (4). 
The three mutant tribrids which are good substrates are 
more difficult to rationalize. The loss of cross-reactivity with 
Y18 for EllA and G14V indicates that these substitutions do 
alter the local surface structure of these peptides in solution. 
In the thrombin-bound peptide structure (8) Glu” is the first 
residue of a P-turn, a position which is compatable with 
alanine, and Gly14 is the last residue of a P-turn, a rather 
unrestricted position (24). Thus these changes may not sig- 
nificantly disrupt the structure of the bound peptide. Perhaps 
more importantly for G14V, the hydrophobic side-chain sub- 
stitution at position 14 can be readily juxtaposed to Va115, 
Phe’, and Leug and therefore may contribute positively to the 
hydrophobic interaction between thrombin and Aa. The find- 
ings with the D7A substitution are most difficult to explain. 
In dysfibrinogenemia Lille Asp7 is replaced by Asn, and this 
protein has a significantly prolonged thrombin time (26). The 
importance of Asp7 has also been indicated by peptide studies 
(5), where the addition of this residue resulted in a 1.5-fold 
increase in kcat. The progress curves indicate that the natural 
sequence is cleaved about 1.5-fold more rapidly than D7A, 
but these two values are within experimental error in our 
data. Given that dysfibrinogen Lille is a poor substrate for 
thrombin, one would expect D7A to also be a poor substrate. 
However, this was not observed. Perhaps the mutation to Asn 
alters the structure differently than the mutation to Ala. 
Together the studies of these altered proteins as inhibitors 
and substrates indicate that the features critical to hydrolysis 
reside in a domain different from those critical to binding. 
Although our data are not sufficiently accurate to detect small 
differences in I&, they do demonstrate that changes which 
alter catalysis by loo-fold or more do not similarly alter 
binding. Thus, our results indicate that residues critical to 
thrombin binding lie outside the region Asp7-Arg”. 
This result is consistent with the existence of a second 
domain in Aa l-50 which interacts with a thrombin site 
outside the catalytic domain. The presence of a second site 
was first proposed when it was found that thrombin binds to 
fibrin (27) and a secondary binding site in fibrinogen has been 
characterized by several groups (28-30). This site is removed 
from the thrombin catalytic site, as demonstrated by the 
finding that thrombin bound to fibrin retains the ability to 
hydrolyze short synthetic substrates and can react with active 
site inhibitors (31). In addition, affinity chromatography 
using immobilized catalytic site-inhibited thrombin demon- 
strates that fragment E from fibrinogen and fragment E from 
fibrin bind equally well to this matrix (30). That is, the loss 
of FpA does not substantially change the affinity of fi- 
brin(ogen) for catalytic site-inhibited thrombin, which sup- 
ports the hypothesis that residues 7-16 do not contribute 
significantly to binding of thrombin to fibrinogen. 
This additional site is thought to have important ionic 
contributions (28-30) and therefore may involve the multiple 
negative side chains found in Aa 30-40 (5 of 11 residues). We 
are in the process of constructing mutant tribrids with sub- 
stitutions in this region, If these mutants have reduced bind- 
ing but unaltered rates of catalysis, this would strongly sup- 
port our hypothesis that binding of the Ao chain of fibrinogen 
to thrombin is dominated by the second site, whereas catalysis 
is controlled by the structure surrounding the cleavage site. 
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